FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280491712> ?p ?o ?g. }

• W4280491712 endingPage "1492" @default.
• W4280491712 startingPage "1479" @default.
• W4280491712 abstract "TETRAXIM™ (Sanofi), a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus (DTaP-IPV) vaccine, has been licensed in South Korea since 2009. In accordance with the Ministry of Food and Drug Safety regulations, this post-marketing surveillance (PMS) study evaluated the safety of the DTaP-IPV vaccine in real-world clinical practice in infants and children who received it as either a part of the three-dose primary series dose at 2, 4, and 6 months or school entry booster between 4 and 6 years of age. This multicenter, observational, PMS study was conducted in real-world practice in South Korea for 6 years (2009–2015) in participants aged between 2 months and 6 years. The study outcomes included solicited reactions, unsolicited adverse events (AEs)/adverse drug reactions (ADRs), unexpected AEs/ADRs, and serious AEs (SAEs)/ADRs. Data from 647 participants was included in the safety analysis. Overall, 268 AEs were reported by 181 (28%) participants: 47 (17.5%) solicited reactions, 220 (82.1%) unsolicited AEs, and 1 (0.4%) unsolicited ADR. A total of 48 AEs (including 47 solicited reactions) were reported to have a causal relationship with the DTaP-IPV vaccine and were reported by 36 (5.6%) participants. A total of 212 unexpected AEs were reported by 152 (23.5%) participants, none of which had a causal relationship with the DTaP-IPV vaccine. Neither immediate AEs nor SAEs were reported during the study. Among the participants who reported AEs, 220 (34%) were on concomitant medications. Most AEs were of mild intensity, and all participants recovered. No safety concerns related to the DTaP-IPV vaccine in a real-world setting were raised in participants aged 2–6 months for the primary series and 4–6 years for the school-entry booster dose in the Korean population. The DTaP-IPV vaccine was well tolerated and can be continued as part of routine immunization programs in infants and children. Trial Registration: NCT01437423." @default.
• W4280491712 created "2022-05-22" @default.
• W4280491712 creator A5004808671 @default.
• W4280491712 creator A5046201638 @default.
• W4280491712 creator A5055891870 @default.
• W4280491712 date "2022-05-14" @default.
• W4280491712 modified "2023-10-18" @default.
• W4280491712 title "Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015" @default.
• W4280491712 cites W1528583251 @default.
• W4280491712 cites W1966687552 @default.
• W4280491712 cites W1972679241 @default.
• W4280491712 cites W2005667876 @default.
• W4280491712 cites W2009451638 @default.
• W4280491712 cites W2016285462 @default.
• W4280491712 cites W2035664449 @default.
• W4280491712 cites W2036251006 @default.
• W4280491712 cites W2049864323 @default.
• W4280491712 cites W2056446778 @default.
• W4280491712 cites W2058104572 @default.
• W4280491712 cites W2068021016 @default.
• W4280491712 cites W2079230513 @default.
• W4280491712 cites W2094040542 @default.
• W4280491712 cites W2108689970 @default.
• W4280491712 cites W2108894573 @default.
• W4280491712 cites W2119949211 @default.
• W4280491712 cites W2130142066 @default.
• W4280491712 cites W2132840565 @default.
• W4280491712 cites W2135038831 @default.
• W4280491712 cites W2137723177 @default.
• W4280491712 cites W2142556359 @default.
• W4280491712 cites W2164970546 @default.
• W4280491712 cites W2260237638 @default.
• W4280491712 cites W2267384356 @default.
• W4280491712 cites W2502272735 @default.
• W4280491712 cites W2525272132 @default.
• W4280491712 cites W2730586781 @default.
• W4280491712 cites W2889939745 @default.
• W4280491712 cites W2900551934 @default.
• W4280491712 cites W2913454200 @default.
• W4280491712 cites W3084304477 @default.
• W4280491712 cites W3094925566 @default.
• W4280491712 cites W3114352800 @default.
• W4280491712 cites W3114466005 @default.
• W4280491712 cites W3120989763 @default.
• W4280491712 cites W3134910224 @default.
• W4280491712 cites W3195799079 @default.
• W4280491712 cites W3197237177 @default.
• W4280491712 cites W3199126057 @default.
• W4280491712 cites W4210975826 @default.
• W4280491712 cites W4229856864 @default.
• W4280491712 cites W4237986257 @default.
• W4280491712 cites W4255177180 @default.
• W4280491712 cites W4292605907 @default.
• W4280491712 cites W4292659332 @default.
• W4280491712 cites W4292809392 @default.
• W4280491712 cites W4300033297 @default.
• W4280491712 doi "https://doi.org/10.1007/s40121-022-00650-8" @default.
• W4280491712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35575974" @default.
• W4280491712 hasPublicationYear "2022" @default.
• W4280491712 type Work @default.
• W4280491712 citedByCount "1" @default.
• W4280491712 countsByYear W42804917122022 @default.
• W4280491712 crossrefType "journal-article" @default.
• W4280491712 hasAuthorship W4280491712A5004808671 @default.
• W4280491712 hasAuthorship W4280491712A5046201638 @default.
• W4280491712 hasAuthorship W4280491712A5055891870 @default.
• W4280491712 hasBestOaLocation W42804917121 @default.
• W4280491712 hasConcept C12590561 @default.
• W4280491712 hasConcept C126322002 @default.
• W4280491712 hasConcept C147483822 @default.
• W4280491712 hasConcept C159047783 @default.
• W4280491712 hasConcept C187212893 @default.
• W4280491712 hasConcept C197934379 @default.
• W4280491712 hasConcept C203014093 @default.
• W4280491712 hasConcept C22070199 @default.
• W4280491712 hasConcept C2522874641 @default.
• W4280491712 hasConcept C2779631682 @default.
• W4280491712 hasConcept C2779841045 @default.
• W4280491712 hasConcept C2780572238 @default.
• W4280491712 hasConcept C2780801004 @default.
• W4280491712 hasConcept C71924100 @default.
• W4280491712 hasConceptScore W4280491712C12590561 @default.
• W4280491712 hasConceptScore W4280491712C126322002 @default.
• W4280491712 hasConceptScore W4280491712C147483822 @default.
• W4280491712 hasConceptScore W4280491712C159047783 @default.
• W4280491712 hasConceptScore W4280491712C187212893 @default.
• W4280491712 hasConceptScore W4280491712C197934379 @default.
• W4280491712 hasConceptScore W4280491712C203014093 @default.
• W4280491712 hasConceptScore W4280491712C22070199 @default.
• W4280491712 hasConceptScore W4280491712C2522874641 @default.
• W4280491712 hasConceptScore W4280491712C2779631682 @default.
• W4280491712 hasConceptScore W4280491712C2779841045 @default.
• W4280491712 hasConceptScore W4280491712C2780572238 @default.
• W4280491712 hasConceptScore W4280491712C2780801004 @default.
• W4280491712 hasConceptScore W4280491712C71924100 @default.
• W4280491712 hasFunder F4320307781 @default.
• W4280491712 hasIssue "4" @default.
• W4280491712 hasLocation W42804917121 @default.

• next